Resources / High-plex spatial proteomic profiling of immunotherapy response groups in head and neck cancer identifies tissues signatures associated with therapy response
Phenoplex™
High-plex spatial proteomic profiling of immunotherapy response groups in head and neck cancer identifies tissues signatures associated with therapy response
Originally presented at SITC 2022
Background

Head and neck squamous cell carcinoma (HNSCC) frequently presents with advanced disease and a poor prognosis. Immunotherapy has shown promising results in patients with metastatic or recurrent (M/R) disease; however, it is only effective in a subset of individuals. Recently, spatial profiling of the tumour microenvironment in HNSCC provided valuable information and new insights into various immune subsets as well as cellular and molecular interactions involved in
immunotherapy response or resistance.

Authors and institutions

Habib Sadeghirad1, Ning Liu2, James Monkman1, Chin Wee Tan2, Caroline Cooper1,3, Sarah E Church4, Dan Winkowski5, Fabian Schneider5, Jeppe Thaagard5, James Mansfield5, Ken O’Byrne3, Melissa Davis2, Brett Hughes6, Arutha Kulasinghe1

    1. The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, QLD, Australia.
    2. The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
    3. Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
    4. Nanostring Technologies, USA.
    5. Visiopharm, Denmark.
    6. Royal Brisbane and Women’s Hospital, Herston, QLD, Australia
Questions? We’re here to help.
Contact us
Success
Your message has been successfully sent!